Search results
Showing 1 to 8 of 8 results for orlistat
This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
View recommendations for TA494Show all sections
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Content Evaluation Quality assurance Medication: Metformin Orlistat Type 2 diabetes prevention: population and community-level
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
This guidance has been replaced by NICE guideline CG43.